Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FOLFOXIRI as perioperative treatment in resectable gastric and GE junction adenocarcinoma
2023-509044-96-00Phase 2Authorised
- Sponsor
- Region Skåne
- Start
- May 2024
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of fluorouracil, oxaliplatin, folinic acid and irinotecan in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma, sponsored by Region Skåne. Primary endpoint: Histopathological response rate. Planned start May 2024; status: authorised.
02
Drugs
fluorouraciloxaliplatinfolinic acidirinotecan
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on 2023-509044-96-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509044-96-00.